Clinical trials
Major Depressive Episode clinical trials
Below are recruiting major depressive episode clinical trials, each written for real people, not researchers. We’re tracking 198 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06963021RecruitingPhase 3
Study of NBI-1065845 for depression that hasn't fully responded to treatment
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
Chino, CaliforniaAges 18 years+ - NCT07592689RecruitingPhase 3
DT120 Treatment for Major Depression
This study tests whether a new medication called DT120 can help people with moderate-to-severe depression feel better. You'd take the medication for several weeks while doctors track your mood and symptoms.
Little Rock, ArkansasAges 18–74 - NCT07573176RecruitingPhase 3
Seltorexant for Depression in Adults and Older Adults
This study tests a new medication called seltorexant as a standalone treatment for major depression. The trial is for adults and older adults who have depression that hasn't improved with other antidepressants or who haven't tried them yet.
Bellflower, CaliforniaAges 18–74 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Huntsville, AlabamaAges 18 years+ - NCT07196501RecruitingPhase 3
Study of a new add-on treatment for depression maintenance
This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.
Oceanside, CaliforniaAges 18 years+ - NCT05757791RecruitingPhase 2
Testing an SGLT2 diabetes drug for depression
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
New York, New YorkAges 18–65 - NCT06633016RecruitingPhase 2
ABX-002 for major depression (add-on treatment)
This trial tests a new medication called ABX-002 as an add-on to your current antidepressant. It's for people with moderate to severe depression who haven't gotten enough help from their current antidepressant alone.
Birmingham, AlabamaAges 18–65 - NCT07684911Recruiting
Long-term effects of TMS for depression
This study looks at how well the benefits of transcranial magnetic stimulation (TMS) last over time for people with depression that didn't get better with other treatments. It also uses brain scans to find markers that might predict who will keep doing well.
RennesAges 18 years+ - NCT06786624RecruitingPhase 3
Testing a new drug for depression that hasn't fully responded to treatment
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Little Rock, ArkansasAges 18 years+ - NCT06913309Recruiting
Home bright light therapy for teen depression
This study tests whether a bright light therapy device you can use at home can help improve depression symptoms in teenagers aged 13-17. It compares the results of using the light with a non-active placebo device.
Beijing, Beijing MunicipalityAges 13–17 - NCT07228468Recruiting
Home brain stimulation for depression
This trial tests if a gentle electrical current applied to the head at home can help reduce symptoms of major depression. You would use a device for short sessions over several weeks, while continuing your usual care.
CardiffAges 18 years+ - NCT05603104RecruitingPhase 3
Medication intensification after first treatment failure in mood and psychosis
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
Ramat GanAges 18–70 - NCT07623135RecruitingPhase 3
Lumateperone for Hard-to-Treat Depression in Older Adults
This study tests lumateperone, a new medication added to your current antidepressant, to help treat depression that hasn't improved with other treatments. It's designed for people age 60 and older who have tried at least two antidepressants without success.
Tucson, ArizonaAges 60 years+ - NCT07127913Recruiting
Closed-loop brain stimulation for hard-to-treat bipolar depression
This trial tests a closed-loop deep brain stimulation system for people with bipolar II disorder whose depression has not responded to standard treatments. The device sends targeted electrical pulses to the brain based on real-time activity, aiming to reduce depression symptoms.
San Francisco, CaliforniaAges 22–70 - NCT06667180RecruitingPhase 1/Phase 2
Low-Intensity Magnetic Stimulation for Major Depression
This study tests whether low-intensity transcranial magnetic stimulation can help treat major depressive disorder and looks at how it affects certain brain chemicals. It's for people currently getting depression treatment who are not pregnant and have no metal implants or certain health conditions.
León, GuanajuatoAges 18–60 - NCT06656416RecruitingPhase 2
ALTO-100 for bipolar depression
This trial tests an investigational drug called ALTO-100 in people with bipolar I or II who are currently experiencing depression. It looks at whether this new medicine can help improve depression symptoms when taken alongside your usual mood stabilizer or antipsychotic medication.
Chandler, ArizonaAges 18–70 - NCT06835855Recruiting
Does mother’s depression affect baby’s attention to emotions?
This study looks at how babies of mothers with depression pay attention to emotional faces. Researchers want to learn if these babies show different patterns of attention to happy or sad cues, which could help understand early development.
Binghamton, New YorkAges 6 months+ - NCT05973643Recruiting
Metabolomics study during ECT for depression
This study measures changes in your blood and/or body chemistry while you receive electroconvulsive therapy (ECT) for a severe mood episode. The goal is to understand biological signals related to ECT and treatment-resistant depression, which may help improve future care.
BronAges 18 years+ - NCT06620276Recruiting
Ketamine and therapy for alcohol use disorder and depression
This trial tests if combining ketamine infusions with weekly therapy can help people who have both alcohol use disorder and hard-to-treat depression. You may qualify if you drink at least moderately, have treatment-resistant depression, and are willing to attend 8 therapy sessions.
Montreal, QuebecAges 18–70 - NCT07412132RecruitingPhase 3
Testing lacosamide for hard-to-treat bipolar depression
This study tests if a medication called lacosamide can help people with bipolar depression that has not improved with at least two other treatments. It's for those with moderate to severe depression in bipolar I or II.
São Paulo, São PauloAges 18–65 - NCT07076407RecruitingPhase 3
Testing a new antidepressant pill for depression
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
Dothan, AlabamaAges 18–74 - NCT06919133Enrolling by invitation
Using smartphone markers to manage depression symptoms
This study tests whether using a smartphone app to track your mood and behavior can help you manage depression symptoms better. You'll use digital tools to monitor your own progress and learn self-management strategies.
FrederiksbergAges 18 years+ - NCT06511908RecruitingPhase 2
Testing a new ketamine-like drug for hard-to-treat depression
This study tests a new experimental drug (2R,6R)-HNK, a chemical related to ketamine, given by IV infusion to see if it can help people with depression that hasn't improved with other treatments. The goal is to find a new option for people who have not found relief from standard antidepressants.
Bethesda, MarylandAges 18–70 - NCT06072898RecruitingPhase 2
Psilocybin brain imaging trial for depression
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
Toronto, OntarioAges 18–64
Hear when a new Major Depressive Episode trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for major depressive episode?
- Yes. Clin2 currently lists 198 recruiting major depressive episode studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a major depressive episode trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a major depressive episode trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.